Cdkn2b (cyclin-dependent kinase inhibitor 2B) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Cdkn2b (cyclin-dependent kinase inhibitor 2B) Rattus norvegicus
Symbol: Cdkn2b
Name: cyclin-dependent kinase inhibitor 2B
RGD ID: 2324
Description: Predicted to enable cyclin-dependent protein serine/threonine kinase inhibitor activity and protein kinase binding activity. Involved in several processes, including cellular response to transforming growth factor beta stimulus; negative regulation of cell cycle G1/S phase transition; and negative regulation of glial cell proliferation. Predicted to be located in cytoplasm and nucleus. Used to study endometrial cancer and renal cell carcinoma. Human ortholog(s) of this gene implicated in carcinoma (multiple); erythema infectiosum; hematologic cancer (multiple); open-angle glaucoma; and urinary bladder cancer. Orthologous to human CDKN2B (cyclin dependent kinase inhibitor 2B); PARTICIPATES IN G1/S transition pathway; cell cycle pathway, mitotic; small cell lung carcinoma pathway; INTERACTS WITH (+)-schisandrin B; 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: cyclin dependent kinase inhibitor 2B; Cyclin dependent kinase inhibitor 2B (p15 inhibits CDK4); Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4); cyclin-dependent kinase 4 inhibitor B; cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4); p14-INK4b; p15; p15-INK4b
RGD Orthologs
Naked Mole-Rat
Alliance Genes
More Info more info ...
Is Marker For: QTLs:   Tcas11  
Candidate Gene For: Emca11
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.25104,009,839 - 104,019,082 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl5104,010,680 - 104,019,050 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx5106,447,506 - 106,453,182 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.05108,177,120 - 108,182,796 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.05108,257,644 - 108,263,335 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.05107,834,353 - 107,857,428 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl5107,845,951 - 107,858,104 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.05111,817,188 - 111,826,334 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.45108,939,669 - 108,945,293 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.15108,946,492 - 108,950,551 (-)NCBI
Celera5102,728,741 - 102,734,427 (-)NCBICelera
Cytogenetic Map5q32NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-schisandrin B  (EXP)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (EXP)
17beta-estradiol  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (EXP)
2-acetamidofluorene  (EXP,ISO)
2-hydroxypropanoic acid  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (EXP)
acetamide  (EXP)
afimoxifene  (ISO)
aflatoxin B1  (EXP,ISO)
all-trans-retinoic acid  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
antimonite  (ISO)
aristolochic acid A  (ISO)
arotinoid acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
auraptene  (ISO)
avobenzone  (ISO)
azathioprine  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
beta-naphthoflavone  (EXP)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (EXP,ISO)
calciol  (ISO)
calcitriol  (ISO)
cannabidiol  (ISO)
cantharidin  (ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
chromium(6+)  (EXP,ISO)
cisplatin  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
coumestrol  (ISO)
crocidolite asbestos  (ISO)
cyclosporin A  (ISO)
cylindrospermopsin  (ISO)
cypermethrin  (EXP)
daunorubicin  (ISO)
diallyl disulfide  (EXP)
diarsenic trioxide  (ISO)
dichlorine  (EXP)
dimethylarsinic acid  (EXP)
dimethylarsinous acid  (ISO)
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate  (ISO)
disodium selenite  (ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
endosulfan  (EXP,ISO)
Enterolactone  (ISO)
entinostat  (ISO)
fenbendazole  (EXP)
flavonoids  (EXP)
fluoxetine  (ISO)
folic acid  (ISO)
formaldehyde  (EXP,ISO)
fumonisin B1  (ISO)
furan  (EXP)
gefitinib  (ISO)
genistein  (ISO)
GW 3965  (ISO)
GW 4064  (ISO)
harmine  (ISO)
hydrogen peroxide  (ISO)
hydroxyurea  (ISO)
indole-3-methanol  (ISO)
lead diacetate  (EXP)
linalool  (ISO)
lithium chloride  (ISO)
manganese(II) chloride  (EXP)
mercury dichloride  (EXP)
methamphetamine  (EXP)
methylparaben  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monobenzyl phthalate  (ISO)
monoethyl phthalate  (ISO)
monosodium L-glutamate  (EXP,ISO)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
nickel dichloride  (EXP)
ochratoxin A  (ISO)
ozone  (EXP)
palbociclib  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP)
pentachlorophenol  (EXP)
phenylmercury acetate  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
pirinixic acid  (ISO)
prednisone  (ISO)
progesterone  (ISO)
quercetin  (ISO)
quercetin 3-O-beta-D-glucofuranoside  (EXP)
quercetin 3-O-beta-D-glucopyranoside  (EXP)
rac-lactic acid  (ISO)
resveratrol  (ISO)
rifampicin  (ISO)
ritonavir  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
SB 431542  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (EXP)
sorafenib  (ISO)
sterigmatocystin  (EXP)
sulfadimethoxine  (EXP)
sunitinib  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (ISO)
tetrachloromethane  (EXP)
thioacetamide  (EXP)
titanium dioxide  (EXP)
tributylstannane  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
urethane  (ISO)
valproic acid  (ISO)
vinclozolin  (EXP)
vorinostat  (ISO)
zinc dichloride  (ISO)
zoledronic acid  (ISO)

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype

References - curated
# Reference Title Reference Citation
1. Rearrangement and allelic imbalance on chromosome 5 leads to homozygous deletions in the CDKN2A/2B tumor suppressor gene region in rat endometrial cancer. Adamovic T, etal., Cancer Genet Cytogenet. 2008 Jul;184(1):9-21.
2. Maternal choline availability alters the localization of p15Ink4B and p27Kip1 cyclin-dependent kinase inhibitors in the developing fetal rat brain hippocampus. Albright CD, etal., Dev Neurosci. 2001;23(2):100-6.
3. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. Arcellana-Panlilio MY, etal., Genes Chromosomes Cancer. 2002 Oct;35(2):176-81.
4. A potential role for p15(Ink4b) and p57(Kip2) in liver development. Awad MM, etal., FEBS Lett. 2000 Oct 20;483(2-3):160-4.
5. Trans-differentiation of alveolar epithelial type II cells to type I cells involves autocrine signaling by transforming growth factor beta 1 through the Smad pathway. Bhaskaran M, etal., J Biol Chem. 2007 Feb 9;282(6):3968-76. Epub 2006 Dec 11.
6. Allelic loss and promoter hypermethylation of the p15INK4b gene features in mouse radiation-induced lymphoid - but not myeloid - leukaemias. Cleary HJ, etal., Leukemia. 1999 Dec;13(12):2049-52.
7. Genetic investigation into the endophenotypic status of central corneal thickness and optic disc parameters in relation to open-angle glaucoma. Dimasi DP, etal., Am J Ophthalmol. 2012 Nov;154(5):833-842.e2. doi: 10.1016/j.ajo.2012.04.023. Epub 2012 Jul 27.
8. Cell cycle regulators in bladder cancer: relationship to schistosomiasis. Eissa S, etal., IUBMB Life. 2004 Sep;56(9):557-64.
9. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Faderl S, etal., Cancer. 2000 Nov 1;89(9):1976-82.
10. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Feng W, etal., Mod Pathol. 2007 Sep;20(9):961-6. Epub 2007 Jul 13.
11. Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-beta1-induced expression of p15/INK4B. Frost SJ, etal., Mol Cell Endocrinol. 2001 May 15;176(1-2):29-37.
12. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
13. Common genetic variants in the 9p21 region and their associations with multiple tumours. Gu F, etal., Br J Cancer. 2013 Apr 2;108(6):1378-86. doi: 10.1038/bjc.2013.7. Epub 2013 Jan 29.
14. Molecular genetic basis of renal carcinogenesis in the Eker rat model of tuberous sclerosis (Tsc2). Hino O, etal., Mol Carcinog 1995 Sep;14(1):23-7.
15. CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy. Hong Q, etal., Exp Ther Med. 2016 May;11(5):1901-1907. Epub 2016 Feb 19.
16. Baicalein induces a dual growth arrest by modulating multiple cell cycle regulatory molecules. Hsu SL, etal., Eur J Pharmacol. 2001 Aug 17;425(3):165-71.
17. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Hu Q, etal., Lab Invest. 2010 Mar;90(3):360-73. doi: 10.1038/labinvest.2009.140. Epub 2010 Jan 11.
18. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Kurakawa E, etal., Int J Oncol. 2001 Aug;19(2):277-81.
19. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Laharanne E, etal., Mod Pathol. 2010 Apr;23(4):547-58. doi: 10.1038/modpathol.2009.196. Epub 2010 Jan 29.
20. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours. Le Frere-Belda MA, etal., Br J Cancer. 2001 Nov 16;85(10):1515-21.
21. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Liu Z, etal., Clin Cancer Res. 2005 Jul 1;11(13):4968-76.
22. Activin A, p15INK4b signaling, and cell competition promote stem/progenitor cell repopulation of livers in aging rats. Menthena A, etal., Gastroenterology. 2011 Mar;140(3):1009-20. doi: 10.1053/j.gastro.2010.12.003. Epub 2010 Dec 11.
23. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
24. Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma. Moad AI, etal., J Cutan Pathol. 2009 Feb;36(2):183-9. doi: 10.1111/j.1600-0560.2008.00989.x. Epub 2008 Jun 17.
25. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
26. Selective loss of resistant alleles at p15(INK4B) and p16(INK4A) genes in chemically-induced rat tongue cancers. Ogawa K, etal., Oral Oncol. 2006 Mar 7;.
27. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
28. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Raj K, etal., Leukemia. 2007 Sep;21(9):1937-44. Epub 2007 Jul 5.
29. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
30. Comprehensive gene review and curation RGD comprehensive gene curation
31. Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome. Rodrigues EF, etal., Leuk Lymphoma. 2010 Oct;51(10):1887-94. doi: 10.3109/10428194.2010.505820.
32. Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells. Schwaller J, etal., Leukemia. 1997 Jan;11(1):54-63.
33. The Pezcoller lecture: cancer cell cycles revisited. Sherr CJ Cancer Res. 2000 Jul 15;60(14):3689-95.
34. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Shimamoto T, etal., Leuk Res. 2005 Jun;29(6):653-9. Epub 2005 Jan 19.
35. High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Tanaka T, etal., Oncogene. 1999 Jun 24;18(25):3793-7.
36. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Teofili L, etal., Leukemia. 2003 May;17(5):919-24.
37. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Tessema M, etal., Leukemia. 2003 May;17(5):910-8.
38. p15INK4b regulates cell cycle signaling in hippocampal astrocytes of aged rats. Wang F and Zhang L, Aging Clin Exp Res. 2015 Nov 2.
39. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Wolff L, etal., Oncogene. 2003 Dec 18;22(58):9265-74.
40. Promoter methylation of P15(INK4B) gene is possibly associated with parvovirus B19 infection in adult acute leukemias. Yalcin A, etal., Int J Lab Hematol. 2009 Aug;31(4):407-19. doi: 10.1111/j.1751-553X.2008.01052.x. Epub 2008 Apr 1.
41. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Yurakh AO, etal., Eur Urol. 2006 Sep;50(3):506-15; discussion 515. Epub 2006 Mar 31.
42. Transforming growth factor-beta antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor. Zhang F, etal., Am J Respir Cell Mol Biol. 2004 Dec;31(6):679-86. Epub 2004 Aug 27.
43. [Methylation of the genes in the 9P21 region in children with acute myeloid leukemia]. Zhang L, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2015 Jan;17(1):6-10.
44. [p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS]. Zhang Y, etal., Zhonghua Xue Ye Xue Za Zhi. 2013 Mar;34(3):237-41. doi: 10.3760/cma.j.issn.0253-2727.2013.03.013.
45. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Zhang Z, etal., Mod Pathol. 2006 Oct;19(10):1339-43. Epub 2006 Jun 23.
Additional References at PubMed
PMID:7712460   PMID:8078588   PMID:9230210   PMID:10812241   PMID:12477932   PMID:12600825   PMID:16943770   PMID:17553787   PMID:17597576   PMID:20501390   PMID:22560297   PMID:23154982  
PMID:26921270   PMID:32080953  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.25104,009,839 - 104,019,082 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl5104,010,680 - 104,019,050 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx5106,447,506 - 106,453,182 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.05108,177,120 - 108,182,796 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.05108,257,644 - 108,263,335 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.05107,834,353 - 107,857,428 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl5107,845,951 - 107,858,104 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.05111,817,188 - 111,826,334 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.45108,939,669 - 108,945,293 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.15108,946,492 - 108,950,551 (-)NCBI
Celera5102,728,741 - 102,734,427 (-)NCBICelera
Cytogenetic Map5q32NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh38922,002,903 - 22,009,313 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl922,002,903 - 22,009,305 (-)EnsemblGRCh38hg38GRCh38
GRCh37922,002,902 - 22,009,312 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36921,992,902 - 21,999,312 (-)NCBINCBI36Build 36hg18NCBI36
Build 34921,992,902 - 21,999,312NCBI
Celera921,941,270 - 21,947,682 (-)NCBICelera
Cytogenetic Map9p21.3NCBI
HuRef921,966,171 - 21,972,582 (-)NCBIHuRef
CHM1_1922,002,731 - 22,009,141 (-)NCBICHM1_1
T2T-CHM13v2.0922,017,276 - 22,023,690 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39489,224,526 - 89,229,269 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl489,224,536 - 89,229,276 (-)EnsemblGRCm39 Ensembl
GRCm38489,306,289 - 89,311,032 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl489,306,299 - 89,311,039 (-)EnsemblGRCm38mm10GRCm38
MGSCv37488,952,198 - 88,956,941 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36488,777,556 - 88,782,190 (-)NCBIMGSCv36mm8
Celera487,792,244 - 87,797,039 (-)NCBICelera
Cytogenetic Map4C4NCBI
cM Map442.15NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_00495547212,275,544 - 12,280,528 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495547212,275,613 - 12,280,141 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan19102,550,897 - 102,560,167 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0921,838,902 - 21,845,355 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1922,455,662 - 22,462,156 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl922,455,662 - 22,462,156 (-)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11141,259,627 - 41,264,832 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1139,933,406 - 39,936,568 (-)NCBIDog10K_Boxer_Tasha
Dog10K_Boxer_Tasha1139,895,530 - 39,924,805 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01142,165,720 - 42,207,150 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1142,165,719 - 42,206,773 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11140,873,681 - 40,876,835 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01140,723,758 - 40,752,953 (-)NCBIUNSW_CanFamBas_1.0
UNSW_CanFamBas_1.01140,761,542 - 40,764,705 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01141,374,892 - 41,378,057 (-)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_024404947155,907,481 - 155,911,659 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049366523,538,986 - 3,581,159 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049366523,576,975 - 3,582,790 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1200,761,004 - 200,766,056 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11200,666,250 - 200,770,880 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21223,955,554 - 223,960,641 (+)NCBISscrofa10.2Sscrofa10.2susScr3
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_00462473625,926,668 - 25,933,440 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462473625,929,314 - 25,933,318 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Cdkn2b
45 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:532
Count of miRNA genes:251
Interacting mature miRNAs:294
Prediction methods:Microtar, Miranda
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
70212Niddm25Non-insulin dependent diabetes mellitus QTL 253.54blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)51131345958Rat
1576314Eutr1Estrogen induced uterine response QTL 1uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)52138965166875058Rat
634305Mamtr1Mammary tumor resistance QTL 10.0001mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)512789751113558310Rat
2290448Scl54Serum cholesterol level QTL 542.93blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)531663789131345958Rat
1576317Eutr2Estrogen induced uterine response QTL 20.01uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)534730116104251008Rat
2316959Gluco59Glucose level QTL 594.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)534944474113558310Rat
1641912Alcrsp18Alcohol response QTL 18response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)535189153141643988Rat
1549845Scl44Serum cholesterol level QTL 446blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)540128307148607290Rat
1331801Rf33Renal function QTL 334.149kidney blood vessel physiology trait (VT:0100012)absolute change in renal vascular resistance (CMO:0001900)543726656129132602Rat
1578766Tcas11Tongue tumor susceptibility QTL 114.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)546711509161317411Rat
1576312Emca8Estrogen-induced mammary cancer QTL 84.1mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)550328551141643988Rat
70189Mcs5Mammary carcinoma susceptibility QTL 510.51mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)555805606132207589Rat
1358895Bp254Blood pressure QTL 2543.60.0003arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)558829236128034027Rat
61426Scl2Serum cholesterol level QTL 27.30.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)559793399143070159Rat
2316957Pur21Proteinuria QTL 216.2urine protein amount (VT:0005160)urine protein level (CMO:0000591)559793528113558156Rat
61393Bp7Blood pressure QTL 74.50.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)560293434161481680Rat
2290005Mcs24Mammary carcinoma susceptibility QTL 24mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)564719390109719390Rat
2306971Anxrr21Anxiety related response QTL 219.47fear/anxiety-related behavior trait (VT:1000241)number of entries into a discrete space in an experimental apparatus (CMO:0000960)566174080124160948Rat
2312671Scl64Serum cholesterol level QTL 640.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)568984307104251008Rat
61380Edpm5Estrogen-dependent pituitary mass QTL 54.50.92pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)568984307104251008Rat
1357396Bw44Body weight QTL 444.19body mass (VT:0001259)body weight (CMO:0000012)568984307104251008Rat
1357402Bw46Body weight QTL 464.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)568984307104251008Rat
2302381Bw84Body weight QTL 844.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)568984307104251008Rat
1354598Srn6Serum renin concentration QTL 63.8blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)569540295151018848Rat
1298070Scl18Serum cholesterol level QTL 183.7blood LDL cholesterol amount (VT:0000181)calculated plasma low density lipoprotein cholesterol level (CMO:0001245)579584860124584860Rat
1598846Bp293Blood pressure QTL 2933.9arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)579584860124584860Rat
1598859Cm66Cardiac mass QTL 662heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)579584860124584860Rat
1302790Scl20Serum cholesterol level QTL 206.40.0001blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)582394392166664054Rat
1298086Bp156Blood pressure QTL 156arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)584132602129132602Rat
7411601Foco12Food consumption QTL 1219.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)587468046132468046Rat
7411564Bw135Body weight QTL 1350.001body mass (VT:0001259)body weight gain (CMO:0000420)587468046132468046Rat
7411582Foco3Food consumption QTL 37.50.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)587468046132468046Rat
6903316Bw113Body weight QTL 11320.0103body mass (VT:0001259)body weight (CMO:0000012)587765973132765973Rat
1358889Bp261Blood pressure QTL 2612.86arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)590067849128034027Rat
1358909Kidm25Kidney mass QTL 251.87kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)590067849128034027Rat
631527Tls1T-lymphoma susceptibility QTL 100.001thymus integrity trait (VT:0010555)post-insult time to onset of T-cell lymphoma (CMO:0001907)590450144135450144Rat
61452Ciaa5CIA Autoantibody QTL 53.5blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)594858972143070159Rat
1331796Thshl2Thyroid stimulating hormone level QTL 22.3blood thyroid-stimulating hormone amount (VT:0005119)serum thyroid stimulating hormone level (CMO:0001248)597059760147465714Rat
2317753Glom24Glomerulus QTL 243.1kidney glomerulus integrity trait (VT:0010546)kidney sclerotic glomeruli count to total glomeruli count ratio (CMO:0001269)597570330136479578Rat
1582212Livw2Liver weight QTL 23.50.0004liver mass (VT:0003402)liver weight to body weight ratio (CMO:0000633)599016066119085810Rat
1358187Emca1Estrogen-induced mammary cancer QTL 14.4mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)599216724148607142Rat
7394708Emca11Estrogen-induced mammary cancer QTL 11mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)599753548113061097Rat
1578673Bmd13Bone mineral density QTL 134.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)5103689353148689353Rat

Markers in Region
D5Lev18   No map positions available.
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.25104,015,134 - 104,015,373 (+)MAPPERmRatBN7.2
Rnor_6.05107,853,470 - 107,853,708NCBIRnor6.0
Rnor_5.05111,822,481 - 111,822,719UniSTSRnor5.0
RGSC_v3.45108,941,440 - 108,941,678UniSTSRGSC3.4
Celera5102,730,512 - 102,730,750UniSTS
Cytogenetic Map5q32UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 1 4 11
Low 23 8 12 8 5 6 9 1 33 5
Below cutoff 30 28 28 7 28 3 5 57 32 4 3


RefSeq Acc Id: ENSRNOT00000008898   ⟹   ENSRNOP00000008898
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl5104,013,794 - 104,018,985 (-)Ensembl
Rnor_6.0 Ensembl5107,852,129 - 107,857,320 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000092196   ⟹   ENSRNOP00000074487
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl5107,845,951 - 107,858,104 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000100738   ⟹   ENSRNOP00000089509
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl5104,013,239 - 104,019,039 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000114223   ⟹   ENSRNOP00000095082
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl5104,010,680 - 104,019,050 (-)Ensembl
RefSeq Acc Id: NM_130812   ⟹   NP_570825
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
mRatBN7.25104,013,363 - 104,019,050 (-)NCBI
Rnor_6.05107,851,701 - 107,857,385 (-)NCBI
Rnor_5.05111,817,188 - 111,826,334 (-)NCBI
RGSC_v3.45108,939,669 - 108,945,293 (-)RGD
Celera5102,728,741 - 102,734,427 (-)NCBI
RefSeq Acc Id: XM_006238380   ⟹   XP_006238442
Rat AssemblyChrPosition (strand)Source
mRatBN7.25104,011,939 - 104,019,016 (-)NCBI
Rnor_6.05107,850,343 - 107,857,317 (-)NCBI
Rnor_5.05111,817,188 - 111,826,334 (-)NCBI
RefSeq Acc Id: XM_006238381   ⟹   XP_006238443
Rat AssemblyChrPosition (strand)Source
mRatBN7.25104,009,839 - 104,019,082 (-)NCBI
Rnor_6.05107,848,177 - 107,857,317 (-)NCBI
Rnor_5.05111,817,188 - 111,826,334 (-)NCBI
RefSeq Acc Id: NP_570825   ⟸   NM_130812
- UniProtKB: P55272 (UniProtKB/Swiss-Prot),   A6JRF4 (UniProtKB/TrEMBL),   Q5PQW4 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006238443   ⟸   XM_006238381
- Peptide Label: isoform X2
- UniProtKB: A0A8I6AMT8 (UniProtKB/TrEMBL),   Q5PQW4 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006238442   ⟸   XM_006238380
- Peptide Label: isoform X1
- UniProtKB: Q5PQW4 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000008898   ⟸   ENSRNOT00000008898
RefSeq Acc Id: ENSRNOP00000074487   ⟸   ENSRNOT00000092196
RefSeq Acc Id: ENSRNOP00000095082   ⟸   ENSRNOT00000114223
RefSeq Acc Id: ENSRNOP00000089509   ⟸   ENSRNOT00000100738

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P55272-F1-model_v2 AlphaFold P55272 1-130 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13693834
Promoter ID:EPDNEW_R4359
Type:initiation region
Description:cyclin-dependent kinase inhibitor 2B
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.05107,857,398 - 107,857,458EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2324 AgrOrtholog
BioCyc Gene G2FUF-40770 BioCyc
Ensembl Genes ENSRNOG00000006735 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000008898.6 UniProtKB/TrEMBL
  ENSRNOT00000100738 ENTREZGENE, UniProtKB/Swiss-Prot
  ENSRNOT00000114223.1 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Ankyrin_rpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ankyrin_rpt-contain_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25164 UniProtKB/Swiss-Prot
Pfam Ank_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Cdkn2b PhenoGen
  ANK_REPEAT UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000006735 RatGTEx
SMART ANK UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF48403 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-03-01 Cdkn2b  cyclin-dependent kinase inhibitor 2B  Cdkn2b  cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2004-09-10 Cdkn2b  cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)    cyclin dependent kinase inhibitor 2B  Name updated 1299863 APPROVED
2002-06-10 Cdkn2b  cyclin dependent kinase inhibitor 2B      Name updated 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_mutations_overexpression homozygous mutant is lethal at 13th day of fetal life; heterozygotes develop renal carcinomas (RCs) in the first year of life 728264